Clinical Trial: NCT06550141
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Status:
RECRUITINGPhase:
Phase 2| Lead Sponsor: | Marcela V. Maus, M.D.,Ph.D. |
| Information Provided By: | Massachusetts General Hospital |
| Last Update Posted: | 2026-10-06 |
Study Overview
Brief Summary
This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL).
The research study involves the following study interventions:
- Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy)
- Axicabtagene Ciloleucel or Lisocabtagene Maraleucel
- Emapalumab
Official Title
A Phase 2 Trial of Emapalumab for the Prevention of CAR-T Cell Associated Toxicities
Conditions
Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
Intervention / Treatment
- Drug: Emapalumab
- Drug: Cyclophosphamide
- Drug: Fludarabine Phosphate
- Drug: Axicabtagene Ciloleucel
- Drug: Dexamethasone
- Drug: Lisocabtagene maraleucel
Other Study ID Numbers
- 24-317
Start Date (Actual)
2024-09-18
Primary Completion Date (Estimated)
2027-08-01
Study Completion Date (Estimated)
2028-08-01
Enrollment (Estimated)
28
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Marcela V. Maus, M.D.,Ph.D. |
| Information Provided By: | Massachusetts General Hospital |
| Last Update Posted: | 2026-10-06 |
Study Overview
Brief Summary
This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL).
The research study involves the following study interventions:
- Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy)
- Axicabtagene Ciloleucel or Lisocabtagene Maraleucel
- Emapalumab
Official Title
A Phase 2 Trial of Emapalumab for the Prevention of CAR-T Cell Associated Toxicities
Conditions
Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
Intervention / Treatment
- Drug: Emapalumab
- Drug: Cyclophosphamide
- Drug: Fludarabine Phosphate
- Drug: Axicabtagene Ciloleucel
- Drug: Dexamethasone
- Drug: Lisocabtagene maraleucel
Other Study ID Numbers
- 24-317
Start Date (Actual)
2024-09-18
Primary Completion Date (Estimated)
2027-08-01
Study Completion Date (Estimated)
2028-08-01
Enrollment (Estimated)
28
Study Type
Interventional
Phase
Phase 2